- Home
- TCRX
as 01-17-2025 4:00pm EST
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 170.1M | IPO Year: | 2021 |
| Target Price: | $11.40 | AVG Volume (30 days): | 544.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.38 - $9.69 | Next Earning Date: | 03-05-2025 |
| Revenue: | $9,362,000 | Revenue Growth: | -44.71% |
| Revenue Growth (this year): | -83.18% | Revenue Growth (next year): | 5.14% |
Stock Insider Trading Activity of TScan Therapeutics Inc. (TCRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | TCRX | 10% Owner | Dec 12 '24 | Buy | $2.95 | 131,800 | $385,768.96 | 5,257,347 | |
| Lynx1 Capital Management LP | TCRX | 10% Owner | Nov 15 '24 | Buy | $4.34 | 947 | $4,113.96 | 5,257,347 |
Latest TScan Therapeutics Inc. News
TCRX Breaking Stock News: Dive into TCRX Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks
MT Newswires
24 days ago
Sector Update: Health Care Stocks Steady Premarket Thursday
MT Newswires
24 days ago
Sector Update: Health Care
MT Newswires
24 days ago
TScan Therapeutics Signs $30 Million Direct Offering; Shares Rise Pre-Bell
GlobeNewswire
24 days ago
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
Simply Wall St.
25 days ago
With 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backing
GlobeNewswire
a month ago
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
GlobeNewswire
a month ago
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
Compare TCRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TCRX TScan Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.